NOVEL HETEROCYCLIC COMPOUND, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Russian patent published in 2020 - IPC C07D401/06 C07D401/14 C07D417/14 C07D413/14 C07D409/14 C07D405/14 C07D471/04 C07D473/40 C07D473/34 C07D473/08 C07D473/06 C07D403/06 A61K31/4184 A61K31/454 A61K31/52 

FIELD: chemistry.

SUBSTANCE: present invention relates to a heterocyclic compound of chemical formula 1, or a pharmaceutically acceptable salt thereof:

[Chemical formula 1]

.

In chemical formula 1: n is equal to 1 or 2, L is -CH₂CH₂-, -CH=C(R')- or -C≡C-, where R' is hydrogen, C_1-4 alkyl or halogen, X₁ is CR₁R₂, NR₁ or -CO-, X₂ is CR₃R₄ or NR₃, where R₁-R₄ , each independently represent hydrogen, C_1-4 alkyl, C_1-4 hydroxyalkyl, hydroxy, amino, carboxy, -COO(C_1-4 alkyl), -CONH₂, -CONH(C_1-4 alkyl), -CON(C_1-4 alkyl)₂, or pyrazolyl, unsubstituted or substituted with C_1-4 haloalkyl; or R₁ and R₃ together with each other link X₁ and X₂ through a double bond, and A is a benzene, pyridine, pyrimidine or pyrimidinedione ring, where A is unsubstituted or substituted with one to three substitutes, each of which is independently selected from group consisting of a ring type substitute, selected from a group consisting of furanyl, imidazolyl, isoxazolyl, phenyl, pyrazolyl, pyridinonyl, pyridinyl, pyrrolyl, thiazolyl and thiophenyl; C_1-4 alkyl; C_1-4 alkoxy; C_1-4 haloalkyl; C_1-4 haloalkoxy; halogen; di(C_1-4 alkyl) amino; nitro; -COO(C_1-4 alkyl); dihydropyranyl; morpholino; piperidinyl; and pyrrolidinyl; and where the ring-type substituent is unsubstituted or substituted with one or two substitutes, each of which is independently selected from a group consisting of C_1-5 alkyl, C_1-4 haloalkyl, C_3-6 cycloalkyl, -COO(C_1-4 alkyl), halogen, cyano, thiazolyl and (1,3-dioxolan-2-yl) methyl. Also presented is a pharmaceutical composition and methods of producing the compound.

EFFECT: disclosed compound has inhibitory action on the enzymatic activity of prolyl-tRNA synthetase (PRS) and can be used for preventing or treating diseases caused by PRS anomaly activity.

15 cl, 3 tbl, 230 ex